Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. It also exports its products to Europe, the United Kingdom, Australia, Sri Lanka, Africa, Philippines, Tanzania, Nigeria, and Commonwealth countries. Bafna Pharmaceuticals Limited was founded in 1981 and is based in Chennai, India. Bafna Pharmaceuticals Limited is a subsidiary of SRJR Lifesciences … Read more
Bafna Pharmaceuticals Limited (BAFNAPH) - Net Assets
Latest net assets as of September 2025: ₹912.28 Million INR
Based on the latest financial reports, Bafna Pharmaceuticals Limited (BAFNAPH) has net assets worth ₹912.28 Million INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹1.61 Billion) and total liabilities (₹694.55 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹912.28 Million |
| % of Total Assets | 56.78% |
| Annual Growth Rate | 16.14% |
| 5-Year Change | 49.38% |
| 10-Year Change | 47.31% |
| Growth Volatility | 62.18 |
Bafna Pharmaceuticals Limited - Net Assets Trend (2005–2025)
This chart illustrates how Bafna Pharmaceuticals Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Bafna Pharmaceuticals Limited (2005–2025)
The table below shows the annual net assets of Bafna Pharmaceuticals Limited from 2005 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹848.07 Million | +4.91% |
| 2024-03-31 | ₹808.39 Million | +10.05% |
| 2023-03-31 | ₹734.55 Million | +18.54% |
| 2022-03-31 | ₹619.64 Million | +9.15% |
| 2021-03-31 | ₹567.71 Million | +10.89% |
| 2020-03-31 | ₹511.95 Million | +171.56% |
| 2019-03-31 | ₹188.52 Million | -49.33% |
| 2018-03-31 | ₹372.02 Million | -11.66% |
| 2017-03-31 | ₹421.12 Million | -26.85% |
| 2016-03-31 | ₹575.71 Million | -20.82% |
| 2015-03-31 | ₹727.13 Million | +4.25% |
| 2014-03-31 | ₹697.48 Million | +2.11% |
| 2013-03-31 | ₹683.04 Million | +5.71% |
| 2012-03-31 | ₹646.17 Million | +19.24% |
| 2011-03-31 | ₹541.89 Million | +32.15% |
| 2010-03-31 | ₹410.05 Million | +6.44% |
| 2009-03-31 | ₹385.23 Million | +224.96% |
| 2008-03-31 | ₹118.55 Million | +29.72% |
| 2007-03-31 | ₹91.39 Million | +60.95% |
| 2006-03-31 | ₹56.78 Million | +33.45% |
| 2005-03-31 | ₹42.55 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bafna Pharmaceuticals Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 43131200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₹236.56 Million | 27.89% |
| Other Comprehensive Income | ₹289.05 Million | 34.08% |
| Other Components | ₹753.76 Million | 88.88% |
| Total Equity | ₹848.07 Million | 100.00% |
Bafna Pharmaceuticals Limited Competitors by Market Cap
The table below lists competitors of Bafna Pharmaceuticals Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Godha Cabcon & Insulation Limited
NSE:GODHA
|
$4.20 Million |
|
Entre Cua Socimi
MC:YENT
|
$4.20 Million |
|
New Concept Energy Inc
NYSE MKT:GBR
|
$4.20 Million |
|
PMVCD
PINK:PMVCD
|
$4.20 Million |
|
Richmond Vanadium Technology Ltd
AU:RVT
|
$4.20 Million |
|
ADUX S.A. EO -25
F:HJMA
|
$4.20 Million |
|
Trius Investments Inc
V:TRU
|
$4.20 Million |
|
Openn Negotiation Ltd
AU:OPN
|
$4.20 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bafna Pharmaceuticals Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 808,390,000 to 848,065,000, a change of 39,675,000 (4.9%).
- Net income of 41,525,000 contributed positively to equity growth.
- Other comprehensive income increased equity by 19,232,000.
- Other factors decreased equity by 21,082,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹41.52 Million | +4.9% |
| Other Comprehensive Income | ₹19.23 Million | +2.27% |
| Other Changes | ₹-21.08 Million | -2.49% |
| Total Change | ₹- | 4.91% |
Book Value vs Market Value Analysis
This analysis compares Bafna Pharmaceuticals Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.05x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 10.82x to 3.05x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-03-31 | ₹10.10 | ₹109.31 | x |
| 2006-03-31 | ₹13.48 | ₹109.31 | x |
| 2007-03-31 | ₹23.64 | ₹109.31 | x |
| 2008-03-31 | ₹15.04 | ₹109.31 | x |
| 2009-03-31 | ₹26.79 | ₹109.31 | x |
| 2010-03-31 | ₹25.66 | ₹109.31 | x |
| 2011-03-31 | ₹31.07 | ₹109.31 | x |
| 2012-03-31 | ₹36.06 | ₹109.31 | x |
| 2013-03-31 | ₹36.43 | ₹109.31 | x |
| 2014-03-31 | ₹36.79 | ₹109.31 | x |
| 2015-03-31 | ₹38.11 | ₹109.31 | x |
| 2016-03-31 | ₹36.23 | ₹109.31 | x |
| 2017-03-31 | ₹23.31 | ₹109.31 | x |
| 2018-03-31 | ₹20.94 | ₹109.31 | x |
| 2019-03-31 | ₹8.06 | ₹109.31 | x |
| 2020-03-31 | ₹216.07 | ₹109.31 | x |
| 2021-03-31 | ₹23.97 | ₹109.31 | x |
| 2022-03-31 | ₹26.19 | ₹109.31 | x |
| 2023-03-31 | ₹31.05 | ₹109.31 | x |
| 2024-03-31 | ₹34.17 | ₹109.31 | x |
| 2025-03-31 | ₹35.79 | ₹109.31 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bafna Pharmaceuticals Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.90%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.85%
- • Asset Turnover: 0.95x
- • Equity Multiplier: 1.81x
- Recent ROE (4.90%) is above the historical average (-3.58%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 21.11% | 3.55% | 1.50x | 3.96x | ₹4.73 Million |
| 2006 | 16.25% | 4.53% | 0.95x | 3.78x | ₹3.55 Million |
| 2007 | 10.60% | 2.60% | 0.69x | 5.91x | ₹545.89K |
| 2008 | 10.11% | 3.03% | 0.77x | 4.31x | ₹129.77K |
| 2009 | 2.77% | 2.26% | 0.61x | 2.02x | ₹-27.85 Million |
| 2010 | 6.05% | 3.30% | 0.89x | 2.05x | ₹-16.19 Million |
| 2011 | 6.18% | 3.31% | 0.75x | 2.50x | ₹-20.71 Million |
| 2012 | 2.88% | 1.43% | 0.59x | 3.43x | ₹-45.41 Million |
| 2013 | 5.87% | 2.25% | 0.67x | 3.86x | ₹-27.83 Million |
| 2014 | 2.04% | 0.76% | 0.79x | 3.42x | ₹-54.82 Million |
| 2015 | 8.61% | 6.32% | 0.49x | 2.78x | ₹-10.01 Million |
| 2016 | -24.29% | -16.44% | 0.44x | 3.33x | ₹-198.02 Million |
| 2017 | -44.74% | -29.38% | 0.36x | 4.18x | ₹-233.53 Million |
| 2018 | -44.13% | -35.48% | 0.34x | 3.65x | ₹-205.29 Million |
| 2019 | -99.02% | -43.25% | 0.37x | 6.27x | ₹-207.76 Million |
| 2020 | -3.67% | -4.42% | 0.60x | 1.40x | ₹-69.89 Million |
| 2021 | 10.26% | 8.18% | 0.82x | 1.52x | ₹1.50 Million |
| 2022 | 8.42% | 6.13% | 0.94x | 1.45x | ₹-9.80 Million |
| 2023 | 15.44% | 9.83% | 0.89x | 1.76x | ₹39.93 Million |
| 2024 | 9.09% | 4.82% | 1.03x | 1.83x | ₹-7.36 Million |
| 2025 | 4.90% | 2.85% | 0.95x | 1.81x | ₹-43.28 Million |
Industry Comparison
This section compares Bafna Pharmaceuticals Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $12,445,167,922
- Average return on equity (ROE) among peers: 14.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bafna Pharmaceuticals Limited (BAFNAPH) | ₹912.28 Million | 21.11% | 0.76x | $4.20 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $802.45 Million | 7.70% | 1.12x | $11.20 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.12 Billion | 12.32% | 2.74x | $149.72 Million |
| Abbott India Limited (ABBOTINDIA) | $42.33 Billion | 33.41% | 0.40x | $1.59 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $15.68 Billion | 32.33% | 0.16x | $1.46 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $123.83 Million |
| Albert David Limited (ALBERTDAVD) | $2.44 Billion | 9.06% | 0.40x | $15.85 Million |
| Alivus Life Sciences Limited (ALIVUS) | $28.17 Billion | 17.24% | 0.21x | $333.13 Million |
| Alkem Laboratories Limited (ALKEM) | $23.74 Billion | 20.90% | 0.71x | $2.41 Billion |
| Alpa Laboratories Limited (ALPA) | $56.73 Million | 0.53% | 2.47x | $5.55 Million |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $2.91 Billion | 13.70% | 0.25x | $77.60 Million |